《沈阳之窗 》 | 是当地最全面的信息,企业发布。媒体营销网络中心
Miura Pharmaceutical Announces Cross‑Domain Leap — From Kampo Heritage to Cell‑L
您当前的位置: > 沈阳之窗 > 新闻 > Miura Pharmaceutical Announces Cross‑Domain Leap — From Kampo Heritage to Cell‑L
Miura Pharmaceutical Announces Cross‑Domain Leap — From Kampo Heritage to Cell‑L
2025-10-17 12:13 来源: 未知 编辑: 系统采编 点击:

 Miura Pharmaceutical Co., Ltd. (“Miura”) today announced a cross‑domain strategy that extends from its Kampo heritage to cell‑level anti‑aging, focusing on preventive healthcare and functional nutrition. Since its founding in 2008, Miura has upheld the mission “to serve human health and keep the tree of life evergreen,” supported by a 20,000‑m² R&D campus, a team of 320 researchers, and 140+ patents. The company has built a collaboration network with 10+ research partners worldwide, including Tokyo Medical University, the California Institute of Technology, and Princeton University.

Technology & Product Innovation

Functional‑food governance system:Miura adheres to Japan’s three‑tier framework—FOSHU (Foods for Specified Health Uses), Nutrient Function Foods, and Foods with Function Claims (FFC)—and complies with MHLW GMP and third‑party testing. All products are screened for radiation and unwanted additives to promote a natural, safe, and effective approach to health.

Oral‑beauty iteration:In May 2023, Miura launched DonCoo 雪白ノ丸 (Yukishiro‑no‑Maru), applying supercritical‑fluid extraction to white tomato (rich in hydrogenated lycopenes), combined with reduced glutathione and Bifida ferment. The product reports an absorption rate of up to 94% and topped both the oral‑beauty and new‑product charts on international e‑commerce platforms in its first month.

Anti‑aging breakthrough:In 2024, Miura introduced DonCoo 还童ノ丸 (Kandō‑no‑Maru), combining catechins with French maritime pine bark extract. Its “four‑in‑one” mechanism—anti‑glycation, antioxidant action, inflammation modulation, and cellular activation—has obtained international patent protection and multi‑country quality certifications.

Global Footprint

Miura’s products reach China, Europe, the Americas, and Southeast Asia. The company advances precision medicine and health technology through collaborations with Peking University Cancer Hospital, the University of Science and Technology of China (USTC), the University of Tokyo, Stanford University, and the University of California system.

Quality & Compliance

Manufacturing conforms to PIC/S, EU, and Japan GMP standards, with third‑party verification to ensure product safety and efficacy.

Industry Impact

Market research indicates the global anti‑aging market reached US$216 billion in 2023. Miura advocates a “healthy age‑forward” paradigm—shifting the conversation from resisting aging to living well with age.

Outlook

Miura will continue to deepen R&D in cell‑level anti‑aging, precision nutrition, and smart antibody therapeutics, aiming to build a leading global health‑tech ecosystem.

About Miura Pharmaceutical

Founded in 2008 and headquartered in Tokyo, Miura innovates across cardiovascular, gastr ointestinal, oral‑beauty, and the skin microbiome fields. The company collaborates broadly with universities worldwide and holds more than 140 patents in Japan and overseas.

相关新闻
美图
美图最新热图·百态故事·大美印象·摄影
沈阳之窗 声明
1.凡注明“来源:沈阳之窗”或"来源:沈阳之窗网"的稿件,均为沈阳之窗的原创稿件,版权均属沈阳之窗所有。未经沈阳之窗报社书面授权,不得进行一切形式的转载、下载或建立镜像等。否则以侵权论,依法追究相关法律责任。
2.凡注明"来源:XXX(非沈阳之窗网)"的作品,均转载自其他媒体。本网转载的目的,在于传递更多信息,并不代表本网赞同其观点和对其真实性负责。
3.如遇转载作品内容、版权问题,以及违法信息、不良信息等问题,请与本网联系。
4.沈阳之窗网用户申请删除信息指南,请点击“删稿流程”——沈阳之窗网删稿申请单
沈阳之窗网联系方式:QQ64975098
Copyright c 2010-2018 http://wvwv.shengyang.jkmi.cn/xinwen/ 新闻 版权所有 欢迎监督举报 如有错误信息 欢迎纠正 QQ64975098